In ₹ Crore except Per Share Latest Annual	BPLPHARMA FY23	JENBURPH FY26	KPL FY24	MAKERSL FY26	Peer Average
Valuation — at last close
P/E	45.39×	—	—	—	—
P/B	5.78×	—	—	◆ 2.05×	2.05× +182%
EV/EBITDA	◆ 51.68×	—	—	156.70×	156.70× -67%
Market Cap	₹1,105 Cr	—	—	₹112 Cr	₹112 Cr +888%
Growth
Revenue CAGR 3Y	—	◆ 7.26%	—	5.77%	6.51%
Revenue CAGR 5Y	—	◆ 9.07%	—	1.55%	5.31%
Net Income CAGR 3Y	—	12.18%	—	—	12.18%
Profitability
EBITDA Margin	9.80%	◆ 23.81%	21.69%	1.45%	15.65% -37%
Net Income Margin	11.16%	◆ 20.59%	—	-3.42%	8.59% +30%
Return on Common Equity	13.63%	◆ 18.84%	—	-3.11%	7.87% +73%
Return on Capital Employed	—	—	19.78%	—	19.78%
Return on Assets	9.25%	◆ 16.45%	—	-2.37%	7.04% +31%
Credit & Quality
Total Debt/Equity	◆ 0.04×	—	0.43×	0.05×	0.24× -83%
Interest Coverage	◆ 7.10×	—	4.54×	-3.91×	0.31× +2154%
Scale — latest FY
Revenue / Total Income	₹218 Cr	₹169 Cr	₹307 Cr	₹50.3 Cr	₹175 Cr +24%
Net Income	₹24.3 Cr	₹34.7 Cr	—	−₹1.7 Cr	₹16.5 Cr +47%
Total Assets	₹308 Cr	₹226 Cr	₹398 Cr	₹73.5 Cr	₹232 Cr +33%
EPS	₹42.14	—	—	₹-2.91	₹-2.91 +1548%
Book Value per Share	₹330.83	—	—	₹92.11	₹92.11 +259%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.